CCM
VNDA icon

Catapult Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Catapult Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$395K Sell
35,000
-25,000
-42% -$306K 0.15% 131
2015
Q2 		$761K Buy
+60,000
New +$647K 0.11% 184

Other funds holding VNDA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Catapult Capital Management's VNDA Position: Q3 2015 in Review

Catapult Capital Management reduced its Vanda Pharmaceuticals (VNDA) stake by 42% in Q3 2015, selling an estimated $306K and leaving 35,000 shares worth $395K. The position accounts for 0.15% of the portfolio, ranked #131.

Catapult Capital Management first reported a position in VNDA in Q2 2015 and has held it in 2 quarters since. The position peaked at $761K in Q2 2015. 122 funds tracked by Wall St. Rank hold VNDA as of Q3 2015.

  • Catapult Capital Management held 35,000 shares of Vanda Pharmaceuticals worth $395K as of Q3 2015.
  • Catapult Capital Management sold 25,000 Vanda Pharmaceuticals shares in Q3 2015, an estimated $306K.
  • Vanda Pharmaceuticals made up 0.15% of Catapult Capital Management's portfolio in Q3 2015, its #131 holding.
  • Catapult Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2015 and has held it in 2 quarters since.
  • Catapult Capital Management's Vanda Pharmaceuticals position peaked at $761K in Q2 2015.
  • 122 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.